10 likes | 110 Views
Lp(a) reduction after different dosing schemes of PCSK9 inhibition. AMG 145 Q2W. AMG 145 Q4W. 0. 70mg (n=75). 105mg (n=76). 140mg (n=73). 280mg (n=78). 350mg (n=79). 420mg (n=77). -10. -18.2. -18.0. LS Mean % change in Lp(a) from baseline to week 12. -20. -22.8.
E N D
Lp(a) reductionafter different dosingschemes of PCSK9 inhibition AMG 145 Q2W AMG 145 Q4W 0 70mg (n=75) 105mg (n=76) 140mg (n=73) 280mg (n=78) 350mg (n=79) 420mg (n=77) -10 -18.2 -18.0 LS Mean % change in Lp(a) from baseline to week 12 -20 -22.8 -23.1 -18 -30 -32.1 -32.3 -40 P<0.001 foreachdose vs. placebo P<0.001 foreachdose vs. placebo Desaiet al.Circulation 2013 July 24